Table 6.
The metallic NPs-based miRNA delivery and their therapeutic effects
| Cell lines | Loaded therapeutic agent | Biological effect | Molecular changes | References |
|---|---|---|---|---|
| Gold nanoparticles (AuNPs) | ||||
| Hep3B and HepG2 | miR-375 | Decreased invasion, colony formation, increased apoptosis, | Down-regulation of Bcl-2, ATG7, YAP1, Up-regulation of cleaved CASPASE 3 | [147] |
| Pca | miR-205 mimic | Decreased invasion, increased apoptosis (when associated with doxo) | Down-regulation of PTEN, E2F1 | [146] |
| U87MG, A549 | miR-208 mimic | Decreased cell viability, small tumor size | NA | [151] |
| Iron oxide nanoparticles (IONPs) | ||||
| C4-2, PC-3 | miR-205 | Increased chemosensitization, apoptosis, cell cycle arrest | Down-regulation of ZEB1, MED1, MMP2, MMP9, | [163] |
| PANC, Mia PaCa-2 | antimiR-21 | Increased invasion/metastasis, small tumor size | Up-regulation of E-CADHERIN, Up-regulation of VIMENTIN, PDCD4, PTEN, BAX, BCL-2 | [156] |
| HPAF-II, AsPC-1 | miR-145 | Decreased proliferation, clonogenicity, invasion, | Up-regulation of MUC13, pAKTSer473 and HER2, p53 | [157] |
| Complex metallic nanoparticles | ||||
| MCF7, MDA, HU02 | miR-101 | Decreased cell viability | NA | [161] |
| MDA-MB-231 and MCF-7 | let-7a, doxorubicin | Decreased chemoresistance, viability, increased apoptosis | NA | [160] |
| MDA-MB-231(A) and MCF-7 cells | anti-miR-21, doxorubicin | Increased apoptosis, high intratumor accumulation | NA | [162] |